Eltrombopag for Treating Chronic Immune (Idiopathic) Thrombocytopenic Purpura (TA293 [Review of TA205])

Technology Appraisal Guidance No. 293

Source: National Institute for Health and Clinical Excellence

NOTE: This guidance replaces ‘NICE technology appraisal guidance 205’ issued in October 2010.

1. Guidance

1.1  Eltrombopag is recommended as an option for treating adults with chronic immune (idiopathic) thrombocytopenic purpura, within its marketing authorisation (that is, in adults who have had a splenectomy and whose condition is refractory to other treatments, or as a second-line treatment in adults who have not had a splenectomy because surgery is contraindicated), only if:

  • their condition is refractory to standard active treatments and rescue therapies, or
  • they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies 

  • the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.

1.2  People currently receiving eltrombopag whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA293 

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205).

Issue Date: July 2013

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in